Single-Center Noninferiority Randomized Trial on the Efficacy and Safety of Low- and High-Dose Rush Oral Milk Immunotherapy for Severe Milk Allergy
© 2020 S. Karger AG, Basel..
INTRODUCTION: Oral immunotherapy (OIT) has been reported to be effective but associated with a risk of severe symptoms. Thus, an OIT method with decreased risk is required.
OBJECTIVES: We aimed to evaluate the efficacy and safety of low- and high-dose OIT regimens in children with severe milk allergy.
METHODS: Overall, 33 participants (median age, 9 years; median final dose of the milk oral food challenge [OFC], 2 mL) were included. The participants were randomly assigned to groups that received either a low (20 mL; n = 19) or high (100 mL; n = 14) maintenance target dose of OIT. The dose was gradually increased to the target dose in the rush escalation phase and was then maintained daily at home. The primary endpoint was the final OFC dose at 6 months of OIT. Adverse events during OIT were evaluated.
RESULTS: The final OFC dose after OIT was significantly higher than that before OIT in both groups (low-dose, p = 0.000; high-dose, p = 0.006), but there was no significant difference in the final OFC dose between the 2 groups (p = 0.767). In the maintenance phase, the high-dose group had significantly more severe symptoms than did the low-dose group (0.5%, 11/2,355 total intake events vs. 0.1%, 4/3,230 total intake events; p = 0.018).
CONCLUSIONS: An equally increased dose effect was observed for maintenance OIT doses of 20 and 100 mL in children with severe milk allergy. The risk of severe symptoms in the maintenance phase was lower in the low-dose group. A low-dose OIT regimen is recommended for severe milk allergy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:181 |
|---|---|
| Enthalten in: |
International archives of allergy and immunology - 181(2020), 9 vom: 09., Seite 699-705 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Takaoka, Yuri [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allergens |
|---|
| Anmerkungen: |
Date Completed 01.02.2021 Date Revised 01.02.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000508627 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311487971 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311487971 | ||
| 003 | DE-627 | ||
| 005 | 20231225142348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000508627 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1038.xml |
| 035 | |a (DE-627)NLM311487971 | ||
| 035 | |a (NLM)32570237 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Takaoka, Yuri |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Single-Center Noninferiority Randomized Trial on the Efficacy and Safety of Low- and High-Dose Rush Oral Milk Immunotherapy for Severe Milk Allergy |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2021 | ||
| 500 | |a Date Revised 01.02.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 S. Karger AG, Basel. | ||
| 520 | |a INTRODUCTION: Oral immunotherapy (OIT) has been reported to be effective but associated with a risk of severe symptoms. Thus, an OIT method with decreased risk is required | ||
| 520 | |a OBJECTIVES: We aimed to evaluate the efficacy and safety of low- and high-dose OIT regimens in children with severe milk allergy | ||
| 520 | |a METHODS: Overall, 33 participants (median age, 9 years; median final dose of the milk oral food challenge [OFC], 2 mL) were included. The participants were randomly assigned to groups that received either a low (20 mL; n = 19) or high (100 mL; n = 14) maintenance target dose of OIT. The dose was gradually increased to the target dose in the rush escalation phase and was then maintained daily at home. The primary endpoint was the final OFC dose at 6 months of OIT. Adverse events during OIT were evaluated | ||
| 520 | |a RESULTS: The final OFC dose after OIT was significantly higher than that before OIT in both groups (low-dose, p = 0.000; high-dose, p = 0.006), but there was no significant difference in the final OFC dose between the 2 groups (p = 0.767). In the maintenance phase, the high-dose group had significantly more severe symptoms than did the low-dose group (0.5%, 11/2,355 total intake events vs. 0.1%, 4/3,230 total intake events; p = 0.018) | ||
| 520 | |a CONCLUSIONS: An equally increased dose effect was observed for maintenance OIT doses of 20 and 100 mL in children with severe milk allergy. The risk of severe symptoms in the maintenance phase was lower in the low-dose group. A low-dose OIT regimen is recommended for severe milk allergy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Efficacy | |
| 650 | 4 | |a Milk allergy | |
| 650 | 4 | |a Oral food challenge test | |
| 650 | 4 | |a Oral immunotherapy | |
| 650 | 4 | |a Safety | |
| 650 | 7 | |a Allergens |2 NLM | |
| 700 | 1 | |a Yajima, Yuko |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Yoichi M |e verfasserin |4 aut | |
| 700 | 1 | |a Kumon, Junko |e verfasserin |4 aut | |
| 700 | 1 | |a Muroya, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Tsurinaga, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Shigekawa, Amane |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Shinichi |e verfasserin |4 aut | |
| 700 | 1 | |a Iba, Norihito |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuji, Taisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Nishikido, Tomoki |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Yukinori |e verfasserin |4 aut | |
| 700 | 1 | |a Doi, Satoru |e verfasserin |4 aut | |
| 700 | 1 | |a Kameda, Makoto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International archives of allergy and immunology |d 1992 |g 181(2020), 9 vom: 09., Seite 699-705 |w (DE-627)NLM012632554 |x 1423-0097 |7 nnns |
| 773 | 1 | 8 | |g volume:181 |g year:2020 |g number:9 |g day:09 |g pages:699-705 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000508627 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 181 |j 2020 |e 9 |b 09 |h 699-705 | ||